Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Merck (MRK) to $113 from $123 and keeps an Equal Weight rating on the ...

Magnificent Seven stocks. Big Tech's runaway growth created gains, but headwinds are forming and some observers doubt the Mag ...

With that acquisition, they got this drug called Winrevair. It is approved by the FDA, just this last year for an almost always fatal disease called pulmonary arterial hypertension.” Cramer ...

We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Merck & Co., Inc.

Bengaluru: Keros Therapeutics said on Wednesday it would voluntarily halt testing of an experimental blood pressure treatment due to safety concerns during a mid-stage trial, causing its shares to ...

MSD's pulmonary arterial hypertension (PAH) drug Winrevair has been accelerating at a breakneck pace since its launch earlier this year – and data from a new phase 3 study could give it a turbo ...

The analyst lowered expectations for Januvia, Bridion, and ex-US Winrevair, while increasing projections for Welireg, Prevymis, and Isentress. Currency fluctuations have also been considered ...

UPDATED: Thursday, Jan. 2 at 1:45 p.m. ET Shortly before the new year, Merck & Co. scored an approval for its potential blockbuster Winrevair in the U.K. The pulmonary arterial hypertension (PAH ...

Further adjustments include revised revenue forecasts for several of Merck's products. The analyst lowered expectations for Januvia, Bridion, and ex-US Winrevair, while increasing projections for ...

The dosing regimen for Winrevair is optimal for balancing safety and effectiveness in adults with PAH, according to clinical ...

The first-in-class activin receptor type IIA-Fc (ActRIIA-Fc) fusion protein, given the trade name Winrevair, has been cleared to improve exercise capacity, improve lung function, and reduce the ...